[go: up one dir, main page]

UY39446A - Micro-nano particles based on dimethyltryptamines and a natural inhibitor of the MAO enzyme - Google Patents

Micro-nano particles based on dimethyltryptamines and a natural inhibitor of the MAO enzyme

Info

Publication number
UY39446A
UY39446A UY0001039446A UY39446A UY39446A UY 39446 A UY39446 A UY 39446A UY 0001039446 A UY0001039446 A UY 0001039446A UY 39446 A UY39446 A UY 39446A UY 39446 A UY39446 A UY 39446A
Authority
UY
Uruguay
Prior art keywords
nano particles
micro
dimethyltryptamines
natural inhibitor
particles based
Prior art date
Application number
UY0001039446A
Other languages
Spanish (es)
Inventor
Carlos Antalich Raibar Alejandro
Original Assignee
Mindcore Labs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mindcore Labs Ltd filed Critical Mindcore Labs Ltd
Priority to UY0001039446A priority Critical patent/UY39446A/en
Priority to EP21218287.7A priority patent/EP4159201A1/en
Priority to US18/697,499 priority patent/US20240408063A1/en
Priority to PCT/CA2022/051451 priority patent/WO2023050010A1/en
Publication of UY39446A publication Critical patent/UY39446A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un proceso de obtención de micro-nano partículas para la encapsulación de DMT/5-MeO-DMT o sus sales derivadas farmacéuticamente aceptables en conjunto con un inhibidor natural de la enzima Monoamino oxidasa (MAO), en dosis terapeuticamente efectivas, para ser usadas en diferentes formulaciones farmacéuticas, para el tratamiento personalizado de trastornos neurológicos y/o psiquiátricos, y/o desórdenes inflamatorios.The present invention relates to a process for obtaining micro-nano particles for the encapsulation of DMT/5-MeO-DMT or its pharmaceutically acceptable salts derived therefrom together with a natural inhibitor of the enzyme Monoamine oxidase (MAO), in therapeutically effective doses, to be used in different pharmaceutical formulations, for the personalized treatment of neurological and/or psychiatric disorders, and/or inflammatory disorders.

UY0001039446A 2021-09-30 2021-09-30 Micro-nano particles based on dimethyltryptamines and a natural inhibitor of the MAO enzyme UY39446A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
UY0001039446A UY39446A (en) 2021-09-30 2021-09-30 Micro-nano particles based on dimethyltryptamines and a natural inhibitor of the MAO enzyme
EP21218287.7A EP4159201A1 (en) 2021-09-30 2021-12-30 Encapsulated microparticles and nanoparticles of dimethyltriptamines
US18/697,499 US20240408063A1 (en) 2021-09-30 2022-09-29 Encapsulated microparticles and nanoparticles of dimethyltriptamines
PCT/CA2022/051451 WO2023050010A1 (en) 2021-09-30 2022-09-29 Encapsulated microparticles and nanoparticles of dimethyltryptamines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UY0001039446A UY39446A (en) 2021-09-30 2021-09-30 Micro-nano particles based on dimethyltryptamines and a natural inhibitor of the MAO enzyme

Publications (1)

Publication Number Publication Date
UY39446A true UY39446A (en) 2023-04-28

Family

ID=96171731

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039446A UY39446A (en) 2021-09-30 2021-09-30 Micro-nano particles based on dimethyltryptamines and a natural inhibitor of the MAO enzyme

Country Status (1)

Country Link
UY (1) UY39446A (en)

Similar Documents

Publication Publication Date Title
EP4570320A3 (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
MX2024008539A (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway.
UY39857A (en) LIPIDATED PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR
UY27755A1 (en) NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND INHIBITORS.
MY208662A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
AR116753A1 (en) PREPARATION PROCESS OF A PYRAZOLSULFONYLAMIDE DERIVATIVE
CY1117995T1 (en) SECONDARY PRODUCTS OF CATEGOLAMIN AND MEDICINES CONTAINING THE THESE COMPOUNDS
CY1115286T1 (en) TOY PARKINSON'S DISEASE TREATMENT METHODS
PA8504801A1 (en) NEW USEFUL BIARILETER DERIVATIVES AS INHIBITORS OF MONOAMINE RECOVERY
EA202193012A1 (en) ROUTES OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
ECSP056019A (en) 2,4-DI (PHENYLAMINE) USEFUL PYRIMIDINS IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND THE IMMUNE SYSTEM
PE20230091A1 (en) THERAPEUTIC CONJUGATES
UY27993A1 (en) DERIVATIVES OF 4-PIRROLIDINO-FENIL-BENCIL ETER
UY39446A (en) Micro-nano particles based on dimethyltryptamines and a natural inhibitor of the MAO enzyme
CL2024003328A1 (en) Methods for the treatment of lymphoma.
TWD209426S (en) The base of the mask transfer box
WO2023069514A9 (en) Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
MD4637B1 (en) Method for producing hyaluronidase conjugate with polyethylenepiperazine derivatives and the use of the conjugate produced
CL2025000075A1 (en) 1,3,4-Oxadiazole derivative compounds that are selective inhibitors of histone deacetylase 6.
SE9804126D0 (en) New pharmaceutical composition
TWD217045S (en) Susceptor support
DE50312224D1 (en) DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
NO20073610L (en) Newly substituted thiophenpyrimidinone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase
TWD204496S (en) Substrate retaining ring
SE0202365D0 (en) New formulation and use thereof